Loading
PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pembrolizumab. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Melanoma, Well-Differentiated Thyroid Cancer. In OnCo, 3 product records name it (Retifanlimab, Sintilimab and Sasanlimab).
In plain words · PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.
PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production.
No product in this corpus aims at PDCD1LG2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Lineage antigen shared with normal lymphoid tissue cells: HPA blood lineage low lineage specificity at or above 25 nTPM, and 3 antibodies (Retifanlimab, Sasanlimab, Sintilimab) aim at it, so normal cells of the lineage are hit too. HPA PDCD1LG2: RNA tissue enhanced (lymphoid tissue 14 nTPM); high antibody staining in 18 normal tissues; highest cancer staining liver cancer (4 of 12 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer (all types), Skin cancer (all types)); approvals of single-target medicines aimed at it also list Anal cancer (squamous cell carcinoma), Lung cancer (all types), Hepatocellular carcinoma, Oesophageal cancer and more, not counted; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PDCD1LG2 tissue; Human Protein Atlas PDCD1LG2 pathology; Open Targets ENSG00000197646 associations
First described 2001. Earliest sequence paper UniProt cites for the protein: Tseng S.-Y. et al, J. Exp. Med, 2001, "B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells". Source.
Sources: HGNC HGNC:18731 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BQ51 (protein name, function text, keywords and locations (REST API)); CIViC gene PDCD1LG2 (1 evidence items, 0 assertions, 1 variants; diseases: Head And Neck Cancer (GraphQL API, CC0)); Open Targets ENSG00000197646 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: breast cancer 0.54 (GraphQL API, CC0)); IntOGen PDCD1LG2 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production. Location: Secreted; Endomembrane system; Cell membrane (UniProt). Locus 9p24.1 (HGNC).
RNA: tissue enhanced (lymphoid tissue 14 nTPM), detected in many normal tissues.
Medium: Adrenal gland, Bone marrow, Breast, Caudate, Cerebellum, Cerebral cortex, Cervix, Endometrium.
Medium only: breast cancer, cervical cancer, endometrial cancer, head and neck cancer.
HPA PDCD1LG2 tissue · HPA PDCD1LG2 pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PDCD1LG2" OR ABSTRACT:"PDCD1LG2" OR TITLE:"programmed cell death 1 ligand 2" OR ABSTRACT:"programmed cell death 1 ligand 2" OR TITLE:"Programmed cell death 1 ligand 2" OR ABSTRACT:"Programmed cell death 1 ligand 2" OR TITLE:"PD-L2" OR ABSTRACT:"PD-L2" OR TITLE:"Btdc" OR ABSTRACT:"Btdc" OR TITLE:"PDL2" OR ABSTRACT:"PDL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDCD1LG2, not a curated reading list.
Shares Papillary thyroid cancer, Thyroid cancer, CIViC, IntOGen.
Shares Thyroid cancer, CIViC, IntOGen, Breast cancer (all types).
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen, Breast cancer (all types).
Shares Thyroid cancer, CIViC, IntOGen, Head and neck squamous cell carcinoma.
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Thyroid cancer, CIViC, IntOGen, Head and neck squamous cell carcinoma.